WALTHAM, Mass., Nov. 26 Millennium Research Group's USHyaluronic Acid (HA) Viscosupplementation Marketrack(TM) service, whichcaptures data from both orthopedic surgeons and rheumatologists, shows thatboth groups provided more HA knee injections in Q3 2007 compared to Q3 2006.While treatments are growing in both groups, there are substantial differencesin the products they use in these procedures.
In the survey sample, from Q3 2006 to Q3 2007, average quarterlyorthopedic surgeon HA knee injection volumes jumped from 62 to nearly 85.Similarly, over the same time period, average quarterly HA knee injections forrheumatologists increased from 54 to over 75. Fueling this growth is thegrowing aging population, which is expanding the potential patient pool for HAviscosupplementation each year. In addition, expanding patient awareness ofthe benefits of HA viscosupplementation injections is also increasing thenumber of patients seeking and ultimately receiving treatment.
"While both groups' injection numbers are rising, they are using differentproducts," says Kevin Flewwelling, Senior Analyst at MRG. "It turns out thatin Q307, orthopedic surgeons mostly used Genzyme's Synvisc, which representednearly 39% of the total injections administered by orthopedic surgeons.Rheumatologists, on the other hand, tended to use sanofi aventis' Hyalgan mostoften, which accounted for almost 36% of the total injections administered bythis group."
When both groups were asked to rank the most important reasons forprescribing HA viscosupplementation, orthopedic surgeons ranked productefficacy as their number one reason, while rheumatologists reported long-termpain relief as their first priority.
About Hyaluronic Acid Viscosupplementation Marketrack(TM)
HA Viscosupplementation Marketrack(TM) gathers data from 260 orthopedicsurgeons, rheumatologists, and other practitioners performing HAViscosupplementation procedures throughout the US. Data is collected on aquarterly basis. Marketrack subscribers receive thousands of data points,including usage (units, average selling price, and revenue), procedurevolumes, distribution channels, competitors, and brand information (Hyalgan,Euflexxa, Orthovisc, Supartz, Synvisc, and others). The project also coversinformation on the competing corticosteroid markets.
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources, Inc.company (www.DecisionResources.com), is the global authority on medicaltechnology market intelligence and a leading provider of strategic informationto the health care sector. Focused solely on the medical device,pharmaceutical, and biotechnology industries, the company provides its clientswith the benefits of its specialized industry expertise through publishedreports and customized consulting services.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holdersFor more information, contact: Amy Krohn Millennium Research Group 416-364-7776 x101 [email protected]
SOURCE Millennium Research Group